Race Oncology Ltd. ( (AU:RAC) ) has issued an update.
Race Oncology Ltd has received human ethics approval from the Bellberry Human Research Ethics Committee to commence its Phase 1 clinical trial of RC220 at Gosford and Wyong Hospitals. This trial aims to evaluate the safety, tolerability, and pharmacokinetics of RC220, both alone and in combination with doxorubicin, in patients with solid tumors. The approval marks a significant milestone for Race Oncology, as it is the second site to receive such approval, following the Southside Cancer Centre. This progress is expected to bolster the company’s momentum in advancing its clinical program and potentially enhance its position in the oncology market.
More about Race Oncology Ltd.
Race Oncology Ltd is a pharmaceutical company focused on developing cancer therapies. The company is engaged in clinical trials to assess the safety and efficacy of its drug candidates, particularly in combination with other treatments, to address unmet medical needs in oncology.
YTD Price Performance: -14.81%
Average Trading Volume: 92,158
Technical Sentiment Signal: Buy
Current Market Cap: A$199.8M
See more data about RAC stock on TipRanks’ Stock Analysis page.